...
首页> 外文期刊>Frontiers in Endocrinology >Endogenous Pancreatic β Cell Regeneration: A Potential Strategy for the Recovery of β Cell Deficiency in Diabetes
【24h】

Endogenous Pancreatic β Cell Regeneration: A Potential Strategy for the Recovery of β Cell Deficiency in Diabetes

机译:内源性胰腺β细胞再生:糖尿病β细胞缺陷恢复的潜在策略

获取原文

摘要

Endogenous pancreatic β cell regeneration is a potential strategy for β cell expansion or neogenesis to treat diabetes. Regeneration can occur through stimulation of existing β cell replication or conversion of other pancreatic cells into β cells. Recently, various strategies and approaches for stimulation of endogenous β cell regeneration have been evaluated, but they were not suitable for clinical application. In this paper, we comprehensively review these strategies, and further discuss various factors involved in regulation of β cell regeneration under physiological or pathological conditions, such as mediators, transcription factors, signaling pathways, and potential pharmaceutical drugs. Furthermore, we discuss possible reasons for the failure of regenerative medicines in clinical trials, and possible strategies for improving β cell regeneration. As β cell heterogeneity and plasticity determines their function and environmental adaptability, we focus on β cell subtype markers and discuss the importance of research evaluating the characteristics of new β cells. In addition, based on the autoimmunologic features of type 1 diabetes, NOD/Lt-SCID-IL2rg ~( null ) (NSG) mice grafted with human immune cells and β cells are recommended for use in evaluation of antidiabetic regenerative medicines. This review will further understand current advances in endogenous β cell regeneration, and provide potential new strategies for the treatment of diabetes focused on cell therapy.
机译:内源性胰腺β细胞再生是治疗糖尿病的β细胞扩增或新生的潜在策略。可以通过刺激现有的β细胞复制或将其他胰腺细胞转化为β细胞来进行再生。近来,已经评估了刺激内源性β细胞再生的各种策略和方法,但是它们不适合临床应用。在本文中,我们全面回顾了这些策略,并进一步讨论了在生理或病理条件下调节β细胞再生的各种因素,例如介体,转录因子,信号通路和潜在的药物。此外,我们讨论了再生药物在临床试验中失败的可能原因,以及改善β细胞再生的可能策略。由于β细胞的异质性和可塑性决定了它们的功能和环境适应性,因此我们将重点放在β细胞亚型标记上,并讨论研究评估新型β细胞特性的重要性。此外,根据1型糖尿病的自身免疫学特征,建议将移植有人免疫细胞和β细胞的NOD / Lt-SCID-IL2rg〜(null)(NSG)小鼠用于评估抗糖尿病再生药物。这篇综述将进一步了解内源性β细胞再生的最新进展,并为以细胞疗法为重点的糖尿病治疗提供潜在的新策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号